PCRX:NSD-Pacira BioSciences, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 73.85

Change

+0.17 (+0.23)%

Market Cap

USD 3.20B

Volume

0.38M

Average Target Price

USD 72.00 (-2.51%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

Company Website : http://www.pacira.com

Address : 5 Sylvan Way, Parsippany, NJ, United States, 07054

Employees : 606

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.26

52 Week High : 77.89

Short Ratio : 17.59

52 Week Low : 27.46

Shorted Shares : 7,054,443

200 Day Moving Average : 59.19

Shorted Shares Previous Month : 6,211,915

50 Day Moving Average : 62.35

Shares Held By Insiders : 7.99%

Short Percentage : 16.00%

Shares Held by Institutions : 116.41%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-19 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

+0.17 (+0.51%)

 USD12.55B N/A N/A
MYL Mylan N.V

N/A

 USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

 USD6.24B N/A N/A
APHA Aphria Inc

+1.19 (+9.58%)

 USD3.96B 41.54 454.68
CRON Cronos Group Inc

+0.16 (+1.46%)

 USD3.93B 38.08 N/A
TLRY Tilray, Inc

+0.39 (+1.98%)

 USD3.12B N/A N/A
IRWD Ironwood Pharmaceuticals, Inc

-0.05 (-0.45%)

 USD1.77B 15.78 14.06
ENDP Endo International plc

-0.06 (-0.84%)

 USD1.64B N/A 9.98
SUPN Supernus Pharmaceuticals, Inc

+0.53 (+1.81%)

 USD1.54B 12.12 7.71
ORGO Organogenesis Holdings Inc

-0.01 (-0.11%)

 USD1.21B 456.50 77.95

ETFs Containing PCRX

Symbol Name Weight Mer Price(Change) Market Cap
EWSC Invesco S&P SmallCap 600 .. 0.00 % 0.40 %

+0.71 (+1.00%)

 USD0.03B
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

+2.43 (+1.33%)

 USD0.48B
PSC Principal U.S. Small-Cap .. 0.00 % 0.38 %

+0.45 (+1.15%)

 USD0.86B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.41% 70% C- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.41% 70% C- 85% B
Trailing 12 Months  
Capital Gain 68.53% 89% B+ 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 68.53% 89% B+ 79% C+
Trailing 5 Years  
Capital Gain 14.12% 73% C 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.12% 73% C 29% F
Average Annual (5 Year Horizon)  
Capital Gain 7.20% 75% C 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.20% 75% C 56% F
Risk Return Profile  
Volatility (Standard Deviation) 25.36% 86% B 57% F
Risk Adjusted Return 28.39% 81% B- 53% F
Market Capitalization 3.20B 95% A 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.14 43% F 41% F
Price/Book Ratio 5.03 43% F 33% F
Price / Cash Flow Ratio 45.39 9% F 9% F
EV/EBITDA 65.69 23% F 14% F
Management Effectiveness  
Return on Equity 27.10% 100% A+ 95% A
Return on Invested Capital 1.60% 81% B- 49% F
Return on Assets 2.51% 86% B 71% C-
Debt to Equity Ratio 86.22% 32% F 27% F
Technical Ratios  
Short Ratio 17.59 4% F 2% F
Short Percent 22.81% 11% F 8% F
Beta 1.26 58% F 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector